Form 4: TELA Bio Director Paul Thomas Receives Equity Grant
Director Equity Grant
Director Paul Thomas was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.
Summary
- Director Paul Thomas acquired 11,925 restricted stock units (RSUs) vesting in three equal annual installments starting June 9, 2027.
- Director Paul Thomas acquired 11,675 RSUs vesting on the earlier of June 9, 2027, the next annual meeting, or a change in control.
- Director Paul Thomas was granted 17,550 stock options with an exercise price of $0.935, vesting in 36 equal monthly installments.
- Director Paul Thomas was granted 17,335 stock options with an exercise price of $0.935, vesting on the earlier of June 9, 2027, the next annual meeting, or a change in control.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership through multi-year vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.
Risks
- Continued service requirements for vesting may impact the director's tenure.
- Market price volatility could affect the value of the granted equity.
Future Outlook
The equity grants are subject to continued service requirements, aligning the director's future performance with the company's long-term strategic goals.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the medical device sector to ensure board alignment with shareholder interests.
Comparison to Industry Standards
- The use of multi-year vesting schedules for director equity is consistent with standard practices for small-cap medical technology companies.
- The combination of RSUs and stock options is a common compensation structure for board members in the healthcare industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of RSUs and stock options to Director Paul Thomas. | 06/09/2026 | Increases director's equity stake in the company. |
Stakeholder Impact
- Shareholders may experience minor dilution upon future exercise of options.
Next Steps
- Vesting of RSUs and options subject to continued service through specified dates.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of grant for RSUs and stock options. |
| 06/09/2027 | Initial vesting date for various equity tranches. |
| 06/09/2036 | Expiration date for stock options. |
Keywords
TELA Bio, TELA, Form 4, Equity Compensation, Director Compensation, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.